Submit a comment
Shigeru Sassa, … , Gregory L. Zalar, Attallah Kappas
Citation Information: J Clin Invest. 1978;61(2):499-508. https://doi.org/10.1172/JCI108961.
Shigeru Sassa, … , Gregory L. Zalar, Attallah Kappas
Published February 1, 1978
Citation Information: J Clin Invest. 1978;61(2):499-508. https://doi.org/10.1172/JCI108961.
Abstract
A 50% reduction in the activity of uroporphyrinogen-I (URO) synthase in liver, erythrocytes, and cultured skin fibroblasts characterizes all patients with clinically active acute intermittent porphyria (AIP). The same enzyme defect has also been demonstrated in the erythrocytes and skin fibroblasts of completely latent gene carriers of this disorder and presumably exists in the liver as well.
Authors
Shigeru Sassa, Gregory L. Zalar, Attallah Kappas
Guidelines
The Editorial Board will only consider comments that are deemed relevant and of interest to readers. The Journal will not post data that have not been subjected to peer review; or a comment that is essentially a reiteration of another comment.
- Comments appear on the Journal’s website and are linked from the original article’s web page.
- Authors are notified by email if their comments are posted.
- The Journal reserves the right to edit comments for length and clarity.
- No appeals will be considered.
- Comments are not indexed in PubMed.
Specific requirements
- Maximum length, 400 words
- Entered as plain text or HTML
- Author’s name and email address, to be posted with the comment
- Declaration of all potential conflicts of interest (even if these are not ultimately posted); see the Journal’s conflict-of-interest policy
- Comments may not include figures
Copyright © 2024 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)